RemeGen forecasts 1H26 net profit of RMB4.70 billion on 433% revenue surge

Bulletin Express08-05

RemeGen Co., Ltd. (RemeGen) released preliminary, unaudited estimates for the six months ended 30 June 2026, signaling a sharp turnaround to profitability driven by strong product sales and a major licensing deal.

Operating revenue is expected to reach RMB5.85 billion, up 433% year on year, representing an increase of RMB4.75 billion compared with RMB1.10 billion in the prior-year period.

Net profit attributable to shareholders is projected at RMB4.70 billion, reversing a net loss of RMB0.45 billion in the first half of 2025. Excluding non-recurring items, core net profit is estimated at RMB4.30 billion, versus a core loss of RMB0.45 billion a year ago.

Management attributes the performance to continued domestic sales growth of the company’s core products—telitacicept and disitamab vedotin—and to an exclusive licensing agreement with AbbVie covering RC148 outside Greater China, which generated substantial technology-licensing revenue.

The figures have not been audited, and final results will be disclosed in the company’s 2026 interim report.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153240242?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153240242","market":"us","top_or_hot":-1,"title":"RemeGen forecasts 1H26 net profit of RMB4.70 billion on 433% revenue surge","media":"Bulletin Express","content":"<p>RemeGen Co., Ltd. (RemeGen) released preliminary, unaudited estimates for the six months ended 30 June 2026, signaling a sharp turnaround to profitability driven by strong product sales and a major licensing deal.</p>\n<p>Operating revenue is expected to reach RMB5.85 billion, up 433% year on year, representing an increase of RMB4.75 billion compared with RMB1.10 billion in the prior-year period.</p>\n<p>Net profit attributable to shareholders is projected at RMB4.70 billion, reversing a net loss of RMB0.45 billion in the first half of 2025. Excluding non-recurring items, core net profit is estimated at RMB4.30 billion, versus a core loss of RMB0.45 billion a year ago.</p>\n<p>Management attributes the performance to continued domestic sales growth of the company’s core products—telitacicept and disitamab vedotin—and to an exclusive licensing agreement with AbbVie covering RC148 outside Greater China, which generated substantial technology-licensing revenue.</p>\n<p>The figures have not been audited, and final results will be disclosed in the company’s 2026 interim report.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RemeGen forecasts 1H26 net profit of RMB4.70 billion on 433% revenue surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRemeGen forecasts 1H26 net profit of RMB4.70 billion on 433% revenue surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-05 19:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>RemeGen Co., Ltd. (RemeGen) released preliminary, unaudited estimates for the six months ended 30 June 2026, signaling a sharp turnaround to profitability driven by strong product sales and a major licensing deal.</p>\n<p>Operating revenue is expected to reach RMB5.85 billion, up 433% year on year, representing an increase of RMB4.75 billion compared with RMB1.10 billion in the prior-year period.</p>\n<p>Net profit attributable to shareholders is projected at RMB4.70 billion, reversing a net loss of RMB0.45 billion in the first half of 2025. Excluding non-recurring items, core net profit is estimated at RMB4.30 billion, versus a core loss of RMB0.45 billion a year ago.</p>\n<p>Management attributes the performance to continued domestic sales growth of the company’s core products—telitacicept and disitamab vedotin—and to an exclusive licensing agreement with AbbVie covering RC148 outside Greater China, which generated substantial technology-licensing revenue.</p>\n<p>The figures have not been audited, and final results will be disclosed in the company’s 2026 interim report.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1153240242","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153240242","pubTimestamp":1785930411,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"RemeGen Co., Ltd. (RemeGen) released preliminary, unaudited estimates for the six months ended 30 June 2026, signaling a sharp turnaround to profitability driven by strong product sales and a major...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"RemeGen 预测 26 年上半年净利润为人民币 47 亿元，收入激增 433%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"RemeGen Co., Ltd. (RemeGen) released preliminary, unaudited estimates for the six months ended 30 June 2026, signaling a sharp turnaround to profitability driven by strong product sales and a major licensing deal.\nOperating revenue is expected to reach RMB5.85 billion, up 433% year on year, representing an increase of RMB4.75 billion compared with RMB1.10 billion in the prior-year period.\nNet profit attributable to shareholders is projected at RMB4.70 billion, reversing a net loss of RMB0.45 billion in the first half of 2025. Excluding non-recurring items, core net profit is estimated at RMB4.30 billion, versus a core loss of RMB0.45 billion a year ago.\nManagement attributes the performance to continued domestic sales growth of the company’s core products—telitacicept and disitamab vedotin—and to an exclusive licensing agreement with AbbVie covering RC148 outside Greater China, which generated substantial technology-licensing revenue.\nThe figures have not been audited, and final results will be disclosed in the company’s 2026 interim report.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153240242","isCrawlerRequest":true}